The charts are showing there's more pain ahead for healthcare stocks, says Carter Worth

Healthcare is cited as the worst-performing sector year to date, with XLV described as setting up for a potential break of a trend line from the 2025 tariff lows. The article also points to a two-year double top and a six-month head-and-shoulders top, while healthcare-relative performance versus the S&P 500 is at 10-year lows. The message is defensive: long or overweight holders are urged to take measures.

Analysis

The important read-through is not just sector weakness, but the market telling us healthcare is no longer the default defensive hiding place. When a traditionally low-beta group loses both absolute trend and relative sponsorship, systematic and discretionary allocators usually keep de-risking for weeks, not days, because underperformance itself becomes the catalyst for redemptions, benchmark pressure, and forced rebalancing.

Second-order effects should show up first in the capital-light end of the ecosystem: managed care and healthcare services tend to absorb the brunt of “defensive rotation failure,” while large-cap pharma can be more resilient if balance sheets are clean and cash yields are supported. Biotech is a different animal: if rates stay stable, weaker sentiment can actually create dispersion rather than uniform downside, with quality names decoupling while speculative small caps remain source-of-funds for investors reducing sector exposure.

The risk to the bearish setup is a macro scare that reignites the sector’s duration and defensiveness premium, or an idiosyncratic policy event that improves reimbursement optics. Absent that, the path of least resistance is lower over the next 1-3 months because trend followers and relative-strength screens are likely still sellers into any bounce, and the market typically needs a new leadership group before healthcare can stabilize.

Contrarian angle: the move may be over-owned on the short side if positioning is already light, which limits crash potential but not further underperformance. That argues for expressing the view through pairs and call spreads rather than naked shorts, because the cleaner trade is to fade healthcare beta while keeping exposure to high-quality balance sheets and secular growers that can survive a weak tape.

Key Decisions for Investors

• Short XLV vs long SPY on any 1-2 day bounce; target a 3-5% relative underperformance over 4-8 weeks, with a tight stop if XLV regains its broken trendline and holds for several sessions.
• Pair long VRTX or LLY vs short IYH/XLV for a quality-vs-sector expression; use a 6-12 week horizon and size for 2:1 upside if relative momentum continues to deteriorate.
• Avoid adding to HMO exposure until relative-strength screens stabilize; if already long UNH/HUM/CNC, trim 25-50% on strength to reduce exposure to a potentially multi-week de-rating.
• For higher convexity, buy put spreads on XLV or IBB 1-2 months out; structure for a modest premium outlay with payoff if the sector loses another 5-7% while implied vol remains contained.
• Watch for a reversal trigger in the form of a broad risk-off macro shock or policy headline; if that occurs, cover tactical shorts quickly because healthcare can re-rate defensively in 3-5 trading sessions.